Division of Cardiology, University of Wisconsin , Madison, Wisconsin.
Nuvaira, Inc. , Minneapolis, Minnesota.
J Appl Physiol (1985). 2019 Jan 1;126(1):67-76. doi: 10.1152/japplphysiol.00565.2018. Epub 2018 Oct 25.
Parasympathetic efferent innervation of the lung is the primary source of lung acetylcholine. Inhaled long-acting anticholinergics improve lung function and symptoms in patients with chronic obstructive pulmonary disease. Targeted lung denervation (TLD), a bronchoscopic procedure intended to disrupt pulmonary parasympathetic inputs, is an experimental treatment for chronic obstructive pulmonary disease. The physiologic and histologic effects of TLD have not previously been assessed. Eleven sheep and two dogs underwent circumferential ablation of the main bronchi with simultaneous balloon surface cooling using a lung denervation system (Nuvaira, Inc., Minneapolis, MN). Changes in pulmonary air flow resistance were monitored before and following TLD. Four animals were assessed for the presence or abolishment of the sensory axon-mediated Hering-Breuer reflex before and following TLD. Six sheep were histologically evaluated 30 days post-TLD for the extent of lung denervation (axonal staining) and effect on peribronchial structures near the treatment site. No adverse clinical effects were seen in any treated animals. TLD produced a ~30% reduction in pulmonary resistance and abolished the sensory-mediated Hering-Breuer reflex. Axonal staining was consistently decreased 60% at 30 days after TLD. All treated airways exhibited 100% epithelial integrity. Damage to other peribronchial structures was minimal. Tissue 1 cm proximal and distal to the treatment was normal, and the esophagus and periesophageal vagus nerve branches were unaffected. TLD treatment effectively denervates the lung while protecting the bronchial epithelium and minimizing effects on peribronchial structures. NEW & NOTEWORTHY The feasibility of targeted lung denervation, a new minimally invasive therapy for obstructive lung disease, has been demonstrated in humans with preliminary clinical studies demonstrating improvement in symptoms, pulmonary function, and exercise capacity in patients with chronic obstructive pulmonary disease. This preclinical animal study demonstrates the ability of targeted lung denervation to disrupt vagal inputs to the lung and details its physiologic and histopathologic effects.
肺的副交感神经传出支配是肺乙酰胆碱的主要来源。吸入长效抗胆碱能药物可改善慢性阻塞性肺疾病患者的肺功能和症状。靶向肺去神经支配(TLD)是一种支气管镜程序,旨在破坏肺副交感神经传入,是慢性阻塞性肺疾病的一种实验性治疗方法。TLD 的生理和组织学效应以前尚未评估过。11 只绵羊和 2 只狗接受了使用肺去神经支配系统(Nuvaira,Inc.,明尼苏达州明尼阿波利斯)进行的主支气管环形消融术,同时进行球囊表面冷却。在 TLD 前后监测肺气流阻力的变化。在 TLD 前后,对 4 只动物进行了感觉轴突介导的 Hering-Breuer 反射的存在或消除的评估。6 只绵羊在 TLD 后 30 天进行组织学评估,以评估肺去神经支配的程度(轴突染色)和对治疗部位附近的支气管周围结构的影响。在任何接受治疗的动物中均未观察到不良的临床影响。TLD 使肺阻力降低约 30%,并消除了感觉介导的 Hering-Breuer 反射。TLD 后 30 天,轴突染色始终降低 60%。所有接受治疗的气道均表现出 100%的上皮完整性。对其他支气管周围结构的损伤最小。距治疗部位 1cm 近端和远端的组织正常,食管和食管周围迷走神经分支未受影响。TLD 治疗可有效地使肺部去神经支配,同时保护支气管上皮并最大程度地减少对支气管周围结构的影响。新的和值得注意的是,针对阻塞性肺部疾病的新型微创治疗方法靶向肺去神经支配的可行性已在人类中得到证实,初步临床研究表明,慢性阻塞性肺疾病患者的症状、肺功能和运动能力得到改善。这项临床前动物研究证明了靶向肺去神经支配破坏肺迷走神经传入的能力,并详细说明了其生理和组织病理学效应。